UC San Diego Shiley Eye Institute UC San Diego Shiley Eye Institute UC San Diego Shiley Eye Institute
by name
Afshari, Natalie A. Brown, Stuart I. Camp, Andrew Chao, Daniel L. Ferrara, Napoleone Ferreyra, Henry A. Freeman, William R. Goldbaum, Michael H. Granet, David B. Haw, Weldon W. Heichel, Chris W. Kikkawa, Don O. Korn, Bobby S. Lee, Jeffrey E. Lin, Jonathan H. Nguyen, Thao P. Nudleman, Eric Robbins, Shira L. Savino, Peter J. Slight, Rigby Weinreb, Robert N. Welsbie, Derek S. Zhang, Kang
by specialty
Comprehensive Ophthalmology Cornea & Refractive Surgery Glaucoma Neuro-Ophthalmology Ophthalmic Genetics Ophthalmic Pathology Ophthalmic Plastic & Reconstructive Surgery Optometry & Low Vision Pediatric Ophthalmology & Eye Alignment Disorders Refractive Surgery / LASIK Retina & Vitreous Thyroid Eye Clinic
by condition
AMD (Age-related Macular Degeneration) Cataracts Corneal Conditions Cosmetic Surgery Diabetic Retinopathy Eye Movement Disorders Glaucoma Hereditary (Genetic) Disorders Low Vision Neuro-Ophthalmic Conditions Ophthalmic Plastic and Reconstructive Surgery Pediatric Conditions Refractive Errors Retinal Diseases Thyroid Eye Disease
Lingyun Cheng, Ph.D.

Lingyun Cheng, Ph.D.

Adjunct Professor
Director of Ocular Pharmacology
Specialty Retina & Vitreous
Graduate School Shanxi Medical University, China
Residency The First Teaching Hospital of Shanxi Medical University, China
Fellowship (1) University of California, San Diego; (2) Ideta Eye Hospital, Japan
Special Interest Ocular drug delivery and vitreoretinal diseases
Publications View on PubMed

Lingyun Cheng, M.D. is an Adjunct Professor and Director of Ocular Pharmacology and an internationally acclaimed physician-scientist in vitreoretinal diseases. A graduate of Shanxi Medical University in China, Cheng completed his residency at The First Teaching Hospital of Shanxi Medical University, China before becoming a vitreoretinal fellow at Ideta Eye Hospital, Japan and then at University of California, San Diego. Dr. Cheng also completed postdoctorate training in ocular pharmacology at the University of California at San Diego.

Dr. Cheng is committed to research in local ocular drug delivery and pharmacological management of vitreoretinal diseases. His team is developing new local ocular drug delivery systems including a new intraocular crystalline lipid prodrug delivery platform, a porous silicon based ocular drug delivery system, and transscleral drug delivery system. These drug delivery systems are an effective approach to achieve a sustained therapeutic drug level in the posterior segment of an eye. With these systems, patients can avoid frequent intravitreal injections for treatment of many refractory vitreoretinal diseases such as macular degeneration and diabetic macular edema. He and his colleague have been published extensively in the area of ocular drug delivery, ocular toxicology, ocular pharmacology, as well as clinical management of vitreoretinal diseases.

Dr. Cheng also actively engages in translational research using various animal models in collaboration with pharmaceutical industry. He is also actively engaged in scientific reviews of publications and grants in his research area.

Faculty

Chairman

Whats Your Symptom Disclaimer

The information contained in this online site is intended to provide accurate and helpful health information for the general public. It is made available with the understanding that the author and publisher are not engaged in rendering medical, health, psychological, or any other kind of personal professional services on this site. The information should not be considered complete and does not cover all diseases, ailments, physical conditions or their treatment. It should not be used in place of a call or visit to a medical, health or other competent professional, who should be consulted before adopting any of the suggestions in this site or drawing inferences from it.

The information about drugs contained on this site is general in nature. It does not cover all possible uses, actions, precautions, side effects, or interactions of the medicines mentioned, nor is the information intended as medical advice for individual problems or for making an evaluation as to the risks and benefits of taking a particular drug.

The operator(s) of this site, and the publisher, specifically disclaim all responsibility for any liability, loss or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the material on this site.

Click Here To Accept

Email Us

First Name*
Last Name*
Email*
Phone
MRN
Topic

Required *

Submit